Search

Recombinant AAV Vectors for Treating Parkinson's, MSA, Gaucher's Disease - US12605467B2

USPTO granted patent US12605467B2 to Shanghai Vitalgen Biopharma Co., Ltd. on April 21, 2026, covering recombinant adeno-associated viral (rAAV) vectors encoding aromatic L-amino acid decarboxylase (AADC), glucocerebrosidase (GBA1), and neurotrophic factors (CDNF or GDNF) for treating neurodegenerative disorders including Parkinson's disease, multiple system atrophy, and Gaucher's disease. The patent contains 14 claims and names three inventors.